JP2023546758A5 - - Google Patents

Info

Publication number
JP2023546758A5
JP2023546758A5 JP2023549957A JP2023549957A JP2023546758A5 JP 2023546758 A5 JP2023546758 A5 JP 2023546758A5 JP 2023549957 A JP2023549957 A JP 2023549957A JP 2023549957 A JP2023549957 A JP 2023549957A JP 2023546758 A5 JP2023546758 A5 JP 2023546758A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence described
bifunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056272 external-priority patent/WO2022087426A1/en
Publication of JP2023546758A publication Critical patent/JP2023546758A/ja
Publication of JP2023546758A5 publication Critical patent/JP2023546758A5/ja
Pending legal-status Critical Current

Links

JP2023549957A 2020-10-23 2021-10-22 アクチビンおよび腫瘍壊死因子-アルファの二機能性アンタゴニストならびにその使用 Pending JP2023546758A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063104765P 2020-10-23 2020-10-23
US63/104,765 2020-10-23
US202063113918P 2020-11-15 2020-11-15
US63/113,918 2020-11-15
PCT/US2021/056272 WO2022087426A1 (en) 2020-10-23 2021-10-22 Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof

Publications (2)

Publication Number Publication Date
JP2023546758A JP2023546758A (ja) 2023-11-07
JP2023546758A5 true JP2023546758A5 (https=) 2024-10-29

Family

ID=81290099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549957A Pending JP2023546758A (ja) 2020-10-23 2021-10-22 アクチビンおよび腫瘍壊死因子-アルファの二機能性アンタゴニストならびにその使用

Country Status (8)

Country Link
US (1) US20230391863A1 (https=)
EP (1) EP4232062A4 (https=)
JP (1) JP2023546758A (https=)
KR (1) KR20230111192A (https=)
AU (1) AU2021365525A1 (https=)
CA (1) CA3196112A1 (https=)
MX (1) MX2023004724A (https=)
WO (1) WO2022087426A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121311510A (zh) * 2023-03-27 2026-01-09 苏州格治生物科技有限公司 含有TNF-α的免疫缀合物及其相关方法和组合物
CN121538222A (zh) * 2026-01-20 2026-02-17 星锐医药(苏州)有限公司 mRNA药物及其在治疗肺动脉高压中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
RU2007117716A (ru) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) Химерный белок
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
CN108290058B (zh) * 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
US11065345B2 (en) * 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers

Similar Documents

Publication Publication Date Title
JP7295146B2 (ja) 抗-ror1抗体およびその用途
JP7438958B2 (ja) 新規な抗体分子、その調製方法及びその使用
JP2021510710A5 (https=)
JP2013507115A5 (https=)
JP2017530692A5 (https=)
JP2019527553A5 (https=)
JP2019513018A5 (https=)
TW201922784A (zh) 4﹘1bb抗體及其製備方法和應用
IL261666B1 (en) Binding proteins and methods of use thereof
HRP20170038T1 (hr) Protutijela na il-6 i njihova uporaba
JP2009526857A (ja) 機能性抗体
JP2022532812A5 (https=)
JP2021512604A5 (https=)
CN112469735A (zh) 用于治疗自发性疾病和癌症的抗cxcl13抗体
KR20240049318A (ko) Fap/cd40 결합 분자 및 이의 의학적 용도
CN114667296A (zh) 一种双特异性抗体及其用途
JP2023546758A5 (https=)
CN110551216B (zh) 多价抗ox40抗体及其用途
CA3208368A1 (en) Vegfa-binding molecules
JP7813704B2 (ja) 抗bcma/抗4-1bb二重特異性抗体及びその用途
JP2021529524A5 (https=)
CN114786720A (zh) TriAx抗体的组合物及其制备和使用方法
JP2023548399A5 (https=)
CN119866346B (zh) 一种抗vegfa抗体或其抗原结合片段及其应用
JP2023546759A5 (https=)